HRP20220111T1 - Protutijela protiv pd-1 - Google Patents
Protutijela protiv pd-1 Download PDFInfo
- Publication number
- HRP20220111T1 HRP20220111T1 HRP20220111TT HRP20220111T HRP20220111T1 HR P20220111 T1 HRP20220111 T1 HR P20220111T1 HR P20220111T T HRP20220111T T HR P20220111TT HR P20220111 T HRP20220111 T HR P20220111T HR P20220111 T1 HRP20220111 T1 HR P20220111T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- set forth
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
Claims (12)
1. Protutijelo koje se veže na ljudski PD-1 (SEQ ID NO: 1), koje sadrži laki lanac (LC) i teški lanac (HC), gdje laki lanac sadrži varijabilno područje lakog lanca (LCVR), a teški lanac sadrži varijabilno područje teškog lanca (HCVR), naznačeno time što:
(1) LCVR ima aminokiselinski slijed dan u SEQ ID NO: 15, a HCVR ima aminokiselinski slijed dan u SEQ ID NO: 12; ili
(2) LCVR ima aminokiselinski slijed dan u SEQ ID NO: 15, a HCVR ima aminokiselinski slijed dan u SEQ ID NO: 13; ili
(3) LCVR ima aminokiselinski slijed dan u SEQ ID NO: 15, a HCVR ima aminokiselinski slijed dan u SEQ ID NO: 14.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, ili SEQ ID NO: 21.
3. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što:
(1) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 16; ili
(2) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 17; ili
(3) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 18; ili
(4) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 19; ili
(5) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 20; ili
(6) LC ima aminokiselinski slijed dan u SEQ ID NO: 22, a HC ima aminokiselinski slijed dan u SEQ ID NO: 21.
4. Protutijelo u skladu s patentnim zahtjevom 2, koje sadrži dva laka lanca i dva teška lanca, naznačeno time što svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 ili SEQ ID NO: 21.
5. Protutijelo u skladu s patentnim zahtjevom 4, naznačeno time što:
(1) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 16; ili
(2) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 17; ili
(3) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 18; ili
(4) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 19; ili
(5) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 20; ili
(6) svaki laki lanac ima aminokiselinski slijed dan u SEQ ID NO: 22, a svaki teški lanac ima aminokiselinski slijed dan u SEQ ID NO: 21.
6. Protutijelo u skladu s patentnim zahtjevom 4 ili 5, naznačeno time što jedan od teških lanaca tvori disulfidnu vezu između lanaca s jednim od lakih lanaca, a drugi teški lanac tvori disulfidnu vezu između lanaca s drugim lakim lancem, dok jedan od teških lanaca tvori dvije disulfidne veze između lanaca s drugim teškim lancem.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačeno time što je protutijelo glikozilirano.
8. Stanica sisavca koja sadrži molekulu DNA koja sadrži polinukleotidni slijed koji kodira polipeptid koji ima aminokiselinski slijed SEQ ID NO: 22 i polinukleotidni slijed koji kodira polipeptid koji ima aminokiselinski slijed SEQ ID NO: 17 ili SEQ ID NO: 20, naznačeno time što stanica može eksprimirati protutijelo koje sadrži laki lanac koji ima aminokiselinski slijed SEQ ID NO: 22 i teški lanac koji ima aminokiselinski slijed SEQ ID NO: 17 ili SEQ ID NO: 20.
9. Postupak proizvodnje protutijela koje sadrži laki lanac koji ima aminokiselinski slijed SEQ ID NO: 22 i teški lanac koji ima aminokiselinski slijed SEQ ID NO: 17 ili SEQ ID NO: 20, naznačen time što se sastoji u uzgoju stanice sisavca u skladu s patentnim zahtjevom 8 u takvim uvjetima da se eksprimira protutijelo, te u prikupljanju eksprimiranog protutijela.
10. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-7, kao i prihvatljivi nosač, razrjeđivač ili pomoćno sredstvo.
11. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeno time što je namijenjeno upotrebi u terapiji, po mogućnosti, namijenjeno upotrebi u liječenju raka, poželjnije, gdje je rak melanom, rak pluća, rak glave i vrata, kolorektalni rak, rak gušterače, rak želuca, rak bubrega, rak mokraćnog mjehura, rak prostate, rak dojke, rak jajnika ili hepatocelularni karcinom.
12. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeno time što je namijenjeno upotrebi u istodobnoj, odvojenoj ili uzastopnoj kombinaciji s jednim ili više antitumorskih sredstava, u liječenju raka, po mogućnosti, gdje je rak melanom, rak pluća, rak glave i vrata, kolorektalni rak, rak gušterače, rak želuca, rak bubrega, rak mokraćnog mjehura, rak prostate, rak dojke, rak jajnika ili hepatocelularni karcinom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/086494 WO2017024465A1 (en) | 2015-08-10 | 2015-08-10 | Pd-1 antibodies |
PCT/CN2016/094122 WO2017025016A1 (en) | 2015-08-10 | 2016-08-09 | Pd-1 antibodies |
EP16834640.1A EP3334824B1 (en) | 2015-08-10 | 2016-08-09 | Pd-1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220111T1 true HRP20220111T1 (hr) | 2022-04-15 |
Family
ID=57982889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220111TT HRP20220111T1 (hr) | 2015-08-10 | 2016-08-09 | Protutijela protiv pd-1 |
Country Status (27)
Country | Link |
---|---|
US (1) | US10316089B2 (hr) |
EP (1) | EP3334824B1 (hr) |
JP (1) | JP6513296B2 (hr) |
KR (1) | KR102132100B1 (hr) |
CN (2) | CN108473977B (hr) |
AR (1) | AR105489A1 (hr) |
AU (1) | AU2016307002B2 (hr) |
BR (1) | BR112018002274B1 (hr) |
CA (1) | CA2990492C (hr) |
CY (1) | CY1124955T1 (hr) |
DK (1) | DK3334824T3 (hr) |
ES (1) | ES2904586T3 (hr) |
HK (1) | HK1255195B (hr) |
HR (1) | HRP20220111T1 (hr) |
HU (1) | HUE058273T2 (hr) |
IL (1) | IL256844B (hr) |
LT (1) | LT3334824T (hr) |
MX (1) | MX365390B (hr) |
MY (1) | MY199019A (hr) |
NZ (1) | NZ738979A (hr) |
PL (1) | PL3334824T3 (hr) |
PT (1) | PT3334824T (hr) |
RS (1) | RS62897B1 (hr) |
RU (1) | RU2686612C1 (hr) |
SI (1) | SI3334824T1 (hr) |
TW (1) | TWI674275B (hr) |
WO (2) | WO2017024465A1 (hr) |
Families Citing this family (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL296026B1 (en) | 2013-09-13 | 2024-06-01 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their uses as drugs and for diagnosis |
KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
BR122020025583B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
MX2017001597A (es) | 2014-08-05 | 2017-11-17 | Cb Therapeutics Inc | Anticuerpos anti-pd-l1. |
SG10201913303XA (en) | 2015-07-13 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
CN108289953B (zh) | 2015-09-29 | 2022-03-11 | 细胞基因公司 | Pd-1结合蛋白及其使用方法 |
SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
DK3500299T3 (da) | 2016-08-19 | 2024-01-29 | Beigene Switzerland Gmbh | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer |
MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
EP3383915A4 (en) * | 2016-10-15 | 2019-07-24 | Innovent Biologics (Suzhou) Co., Ltd. | PD-1 ANTIBODY |
WO2018081621A1 (en) | 2016-10-28 | 2018-05-03 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
EA201990875A1 (ru) | 2016-11-03 | 2019-09-30 | Бристол-Маерс Сквибб Компани | Активируемые антитела против ctla-4 и их применение |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
JP7275030B2 (ja) | 2017-01-20 | 2023-05-17 | タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド | 抗pd-1抗体およびその使用 |
TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
AU2018229278A1 (en) | 2017-02-28 | 2019-10-17 | Sanofi | Therapeutic RNA |
EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
HRP20231457T1 (hr) | 2017-05-30 | 2024-05-10 | Bristol-Myers Squibb Company | Liječenje lag-3-pozitivnih tumora |
US20210340250A1 (en) | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
KR20200011447A (ko) | 2017-05-30 | 2020-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
CN117462668A (zh) | 2017-06-01 | 2024-01-30 | 百时美施贵宝公司 | 用抗pd-1抗体治疗肿瘤的方法 |
WO2019001417A1 (en) * | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA |
AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
WO2019014402A1 (en) | 2017-07-14 | 2019-01-17 | Innate Tumor Immunity, Inc. | MODULATORS OF NLRP3 |
JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 腫瘍処置法 |
MX2020004349A (es) | 2017-11-06 | 2020-10-05 | Bristol Myers Squibb Co | Metodos de tratamiento de un tumor. |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
WO2019129137A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
AU2019210332A1 (en) | 2018-01-22 | 2020-09-10 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
JP2021511344A (ja) | 2018-01-22 | 2021-05-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 癌を治療する組成物および方法 |
WO2019153200A1 (zh) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
EA202092262A1 (ru) | 2018-03-23 | 2021-01-14 | Эли Лилли Энд Компани | Антитела против cd137 для комбинации с антителами против pd-1 |
US20210032344A1 (en) | 2018-03-30 | 2021-02-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
CA3095897A1 (en) * | 2018-04-02 | 2019-10-10 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
PE20210160A1 (es) | 2018-04-25 | 2021-01-26 | Innate Tumor Immunity Inc | Moduladores de nlrp3 |
BR112020022265A2 (pt) | 2018-05-07 | 2021-02-23 | Genmab A/S | método para tratar câncer em um indivíduo, e, estojo. |
CN112236455B (zh) | 2018-05-17 | 2023-05-16 | 南京维立志博生物科技有限公司 | 结合pd-1的抗体及其用途 |
JP7455806B2 (ja) * | 2018-07-18 | 2024-03-26 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | キノリン誘導体と抗体による薬物の組み合わせ |
EP3823991A4 (en) * | 2018-07-19 | 2022-08-03 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF |
CN112334488B (zh) * | 2018-07-19 | 2023-12-08 | 伊莱利利公司 | 靶向免疫检查点的双特异性抗体 |
AU2019310803B2 (en) | 2018-07-25 | 2022-11-03 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-TIGIT antibody and uses thereof |
US20210238287A1 (en) | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
CN113038989A (zh) | 2018-08-16 | 2021-06-25 | 先天肿瘤免疫公司 | 咪唑并[4,5-c]喹啉衍生的nlrp3调节剂 |
CN112996567A (zh) | 2018-08-16 | 2021-06-18 | 先天肿瘤免疫公司 | 咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂 |
CN112888677A (zh) | 2018-08-16 | 2021-06-01 | 先天肿瘤免疫公司 | 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法 |
US20210213102A1 (en) | 2018-09-21 | 2021-07-15 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
AU2019343251B2 (en) | 2018-09-21 | 2022-06-09 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin 2 and use thereof |
CN111253486B (zh) * | 2018-09-27 | 2023-09-29 | 再鼎医药(上海)有限公司 | 抗pd-1抗体及其用途 |
CA3114173A1 (en) * | 2018-09-27 | 2020-04-02 | Musc Foundation For Research Development | Pharmaceutical combination for the treatment of cancer |
KR20210072059A (ko) | 2018-10-09 | 2021-06-16 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-MerTK 항체 |
SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
WO2020086724A1 (en) | 2018-10-23 | 2020-04-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
CN111100846A (zh) * | 2018-10-26 | 2020-05-05 | 上海元宋生物技术有限公司 | 表达pd-1结合蛋白的溶瘤病毒及其应用 |
SG11202104969RA (en) | 2018-11-16 | 2021-06-29 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
EP3891508A1 (en) | 2018-12-04 | 2021-10-13 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
EP3666905A1 (en) | 2018-12-11 | 2020-06-17 | Sanofi | E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer |
JP2022514702A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗pd-1/il-7分子 |
KR20210107062A (ko) | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 이작용성 항-PD-1/SIRPα 분자 |
JP7340021B2 (ja) | 2018-12-23 | 2023-09-06 | エフ. ホフマン-ラ ロシュ アーゲー | 予測腫瘍遺伝子変異量に基づいた腫瘍分類 |
CN111423510B (zh) | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
BR112021010703A2 (pt) | 2019-01-11 | 2021-08-24 | Eli Lilly And Company | Uso de um anticorpo tim-3 antihumano para o tratamento de câncer e uso de umacomposição farmacêutica compreendendo um anticorpo tim-3 anti-humano para o tratamento de câncer |
EP3911642A1 (en) | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US20220089572A1 (en) | 2019-01-14 | 2022-03-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
EP3911416B1 (en) | 2019-01-14 | 2024-06-12 | Innate Tumor Immunity, Inc. | Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer |
ES2930151T3 (es) | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
TW202043274A (zh) | 2019-01-21 | 2020-12-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
CA3128987A1 (en) * | 2019-02-04 | 2020-08-13 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
CN113677402A (zh) | 2019-03-28 | 2021-11-19 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
JP2022526960A (ja) | 2019-03-28 | 2022-05-27 | ブリストル-マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
US20220235132A1 (en) * | 2019-06-05 | 2022-07-28 | Anaptysbio, Inc. | Pd-1 agonist and method of using same |
KR20220030956A (ko) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
BR112022004316A2 (pt) | 2019-09-22 | 2022-06-21 | Bristol Myers Squibb Co | Caracterização espacial quantitativa para terapia de antagonista lag-3 |
CA3152263A1 (en) | 2019-09-25 | 2021-04-01 | Julia SANTUCCI PEREIRA DEL BUONO | Composite biomarker for cancer therapy |
JP2022552323A (ja) | 2019-10-15 | 2022-12-15 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ/エステラーゼ欠損哺乳動物細胞株 |
EP4056200A4 (en) * | 2019-11-04 | 2024-01-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINATION OF DRUGS OF A QUINOLINE DERIVATIVE AND A PD -1 MONOCLONAL ANTIBODY |
WO2021092044A1 (en) | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
IL293364A (en) | 2019-11-27 | 2022-07-01 | Gi Innovation Inc | A pharmaceutical preparation for the treatment of cancer containing fusion proteins containing protein 2-il and protein 80cd and immune checkpoint inhibitors |
WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
CN115243721A (zh) | 2019-12-19 | 2022-10-25 | 百时美施贵宝公司 | Dgk抑制剂和检查点拮抗剂的组合 |
TW202128224A (zh) * | 2019-12-23 | 2021-08-01 | 大陸商信達生物製藥(蘇州)有限公司 | 抗pd-1抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 |
WO2021142203A1 (en) | 2020-01-10 | 2021-07-15 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2021143671A1 (zh) * | 2020-01-13 | 2021-07-22 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和喹唑啉衍生物的药物组合以及其用途、使用其的方法 |
EP4097234A1 (en) | 2020-01-28 | 2022-12-07 | Université de Strasbourg | Antisense oligonucleotide targeting linc00518 for treating melanoma |
BR112022014962A2 (pt) | 2020-01-30 | 2022-09-20 | Ona Therapeutics S L | Terapia de combinação para tratamento de câncer e metástase de câncer |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
EP4114398A1 (en) | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
BR112022016720A2 (pt) | 2020-03-06 | 2022-11-16 | Ona Therapeutics S L | Anticorpos anti-cd36 e seu uso para tratamento de câncer |
IL296437A (en) | 2020-03-18 | 2022-11-01 | Gi Innovation Inc | A pharmaceutical preparation for the treatment of cancer containing a fusion protein containing the 2-il protein and the 80-cd protein and an anti-cancer drug |
BR112022018636A2 (pt) | 2020-03-23 | 2023-01-31 | Bristol Myers Squibb Co | Anticorpos anti-ccr8 para tratamento de câncer |
WO2021222711A1 (en) * | 2020-05-01 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Neutralizing antibody assay for therapeutic proteins |
IL297748A (en) | 2020-05-01 | 2022-12-01 | Ngm Biopharmaceuticals Inc | ilt binding agents and methods of using them |
JP2023525082A (ja) | 2020-05-07 | 2023-06-14 | アンスティテュ・クリー | 免疫抑制線維芽細胞集団のバイオマーカーとしてのantxr1及び免疫療法に対する応答を予測するためのその使用 |
TW202144409A (zh) * | 2020-05-12 | 2021-12-01 | 大陸商信達生物制藥(蘇州)有限公司 | 抗vegf抗體和抗pd-1抗體組合用於預防或治療疾病的應用 |
IL298993A (en) | 2020-07-07 | 2023-02-01 | BioNTech SE | Therapeutic RNA for HPV positive cancer |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
BR112023003553A2 (pt) | 2020-08-31 | 2023-04-04 | Bristol Myers Squibb Co | Assinatura de localização celular e imunoterapia |
JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
CA3193688A1 (en) | 2020-10-09 | 2022-04-14 | Vladimir Lazar | Novel prediction method and gene signatures for the treatment of cancer |
WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
MX2023004847A (es) | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
MX2023005528A (es) | 2020-11-17 | 2023-06-23 | Seagen Inc | Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1. |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
CN114601924A (zh) * | 2020-12-09 | 2022-06-10 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法 |
CA3201729A1 (en) | 2020-12-17 | 2022-06-23 | Nicolas Poirier | Bifunctional anti-pd1/il-7 molecules |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
PE20240820A1 (es) | 2020-12-28 | 2024-04-18 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de los mismos |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
TWI825544B (zh) | 2020-12-31 | 2023-12-11 | 大陸商信達生物製藥(蘇州)有限公司 | 含異二聚體抗體Fc的蛋白以及其製備方法 |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
CA3206241A1 (en) * | 2021-01-29 | 2022-01-28 | Guoqing Cao | Antigen binding protein and use thereof |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
CN113621066A (zh) * | 2021-08-31 | 2021-11-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1抗体及其晶体制备方法 |
WO2023040804A1 (zh) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和化疗药的药物组合及其使用方法 |
KR20240082364A (ko) | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
CA3234647A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2023211068A1 (ko) | 2022-04-25 | 2023-11-02 | 웰마커바이오 주식회사 | 항-igsf1 항체 및 항-pd-1 항체를 포함하는 암 치료용 약학 조성물 |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
WO2024023740A1 (en) | 2022-07-27 | 2024-02-01 | Astrazeneca Ab | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2925551A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
PL367162A1 (en) | 2001-04-02 | 2005-02-21 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
SI2206517T1 (sl) | 2002-07-03 | 2023-12-29 | Ono Pharmaceutical Co., Ltd. | Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1 |
AU2003288675B2 (en) * | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトpd−1に対し特異性を有する物質 |
GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
AU2005295038B2 (en) | 2004-10-06 | 2012-05-17 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ProgrammedDeath1(PD−1)に対するヒトモノクローナル抗体および抗PD−1抗体単独または他の免疫療法と併用した癌治療方法 |
RU2596491C2 (ru) | 2005-06-08 | 2016-09-10 | Дана-Фарбер Кэнсер Инститьют | Способы и композиции для лечения персистирующих инфекций |
KR101523391B1 (ko) * | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
EP2225397A4 (en) | 2007-11-28 | 2011-08-17 | Univ Montreal | PD-1 MODULATION AND USES THEREOF |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Pd−1特異抗体およびその使用 |
KR101924874B1 (ko) * | 2008-09-26 | 2018-12-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
RU2633509C2 (ru) * | 2011-03-31 | 2017-10-12 | Мерк Шарп И Доум Корп. | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения |
PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
TW201840336A (zh) * | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
EP3633377A1 (en) * | 2013-03-15 | 2020-04-08 | F. Hoffmann-La Roche AG | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
WO2015036394A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune Limited | Antibodies against pd-1 and uses thereof |
IL296026B1 (en) | 2013-09-13 | 2024-06-01 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their uses as drugs and for diagnosis |
EA035037B1 (ru) * | 2013-12-12 | 2020-04-21 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение |
-
2015
- 2015-08-10 WO PCT/CN2015/086494 patent/WO2017024465A1/en active Application Filing
-
2016
- 2016-07-26 TW TW105123623A patent/TWI674275B/zh active
- 2016-07-26 AR ARP160102270A patent/AR105489A1/es unknown
- 2016-08-09 DK DK16834640.1T patent/DK3334824T3/da active
- 2016-08-09 BR BR112018002274-8A patent/BR112018002274B1/pt active IP Right Grant
- 2016-08-09 HR HRP20220111TT patent/HRP20220111T1/hr unknown
- 2016-08-09 US US15/232,026 patent/US10316089B2/en active Active
- 2016-08-09 WO PCT/CN2016/094122 patent/WO2017025016A1/en active Application Filing
- 2016-08-09 PL PL16834640T patent/PL3334824T3/pl unknown
- 2016-08-09 MX MX2018001671A patent/MX365390B/es active IP Right Grant
- 2016-08-09 CA CA2990492A patent/CA2990492C/en active Active
- 2016-08-09 EP EP16834640.1A patent/EP3334824B1/en active Active
- 2016-08-09 SI SI201631425T patent/SI3334824T1/sl unknown
- 2016-08-09 PT PT168346401T patent/PT3334824T/pt unknown
- 2016-08-09 IL IL256844A patent/IL256844B/en unknown
- 2016-08-09 NZ NZ73897916A patent/NZ738979A/en unknown
- 2016-08-09 CN CN201680040482.0A patent/CN108473977B/zh active Active
- 2016-08-09 ES ES16834640T patent/ES2904586T3/es active Active
- 2016-08-09 LT LTEPPCT/CN2016/094122T patent/LT3334824T/lt unknown
- 2016-08-09 HU HUE16834640A patent/HUE058273T2/hu unknown
- 2016-08-09 JP JP2018526983A patent/JP6513296B2/ja active Active
- 2016-08-09 KR KR1020187003720A patent/KR102132100B1/ko active IP Right Grant
- 2016-08-09 RU RU2018104547A patent/RU2686612C1/ru active
- 2016-08-09 CN CN201910309687.XA patent/CN110003339B/zh active Active
- 2016-08-09 MY MYPI2018700519A patent/MY199019A/en unknown
- 2016-08-09 AU AU2016307002A patent/AU2016307002B2/en active Active
- 2016-08-09 RS RS20220077A patent/RS62897B1/sr unknown
-
2018
- 2018-11-08 HK HK18114318.6A patent/HK1255195B/zh unknown
-
2022
- 2022-01-07 CY CY20221100019T patent/CY1124955T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220111T1 (hr) | Protutijela protiv pd-1 | |
AR105654A1 (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
HRP20202024T1 (hr) | Cd3-vežuća domena | |
HRP20192059T1 (hr) | Protutijela protiv tau i njihova upotreba | |
RU2017102312A (ru) | Конструкции мультиспецифичных антител | |
HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
HRP20171608T1 (hr) | Protutijela koja vežu albumin i njihovi vezujući fragmenti | |
HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
JP2017529067A5 (hr) | ||
HRP20211703T1 (hr) | Protutijela protiv pd-1 i njihova upotreba | |
BR112014001573B8 (pt) | Molécula fv ao antígeno multivalente | |
WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
FI3378535T3 (fi) | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
JP2020503001A5 (hr) | ||
RU2017102193A (ru) | Конструкции полиспецифических антител | |
HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
EP2371866A3 (en) | Multivalent antigen-binding Fv molecule | |
HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf |